



LUMOS
DIAGNOSTICS

ASX ANNOUNCEMENT

1H FY24 Results Investor Briefing Invitation

MELBOURNE, Australia (23 February 2024) – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, will be reporting its 1H FY24 financial results on Wednesday, 28 February 2024.

Following the release, the Company invites investors and analysts to attend an online briefing later that morning at 10.30am (AEDT).

During the briefing, Chief Executive Officer, Doug Ward; Chief Financial Officer, Barrie Lambert, and Senior VP Commercial Operations, Paul Kase will present an overview of the results and discuss recent progress. This will be followed by a Q+A session.

Participants can pre-register ahead of time via the following link:

https://us02web.zoom.us/webinar/register/WN_7wqk9aJITOC3Ay86Fvm71g

Once the registration form is completed, investors will receive a confirmation email with details on how to access the briefing. If you would like to ask a question during the briefing, please send your question ahead of the session to: jane.lowe@irdepartment.com.au.

The Lumos team looks forward to welcoming those shareholders and potential investors who are able to attend.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

For personal use only

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 (0) 423 139 163

Investor Contact:

Jane Lowe
Managing Director, IR Department
ir@lumosdiagnostics.com
+61 411 117 774

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205, Australia
+61 3 9087 1598

For personal use only